SIGA TechnologiesSIGA
SIGA
About: SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Employees: 45
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
94% more call options, than puts
Call options by funds: $7.74M | Put options by funds: $3.99M
22% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 46
12% more funds holding
Funds holding: 151 [Q2] → 169 (+18) [Q3]
2.0% more ownership
Funds ownership: 48.05% [Q2] → 50.05% (+2.0%) [Q3]
7% less capital invested
Capital invested by funds: $259M [Q2] → $241M (-$18.2M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for SIGA.
Financial journalist opinion
Based on 4 articles about SIGA published over the past 30 days
Neutral
Zacks Investment Research
5 days ago
Siga Technologies Inc. (SIGA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $6.34, denoting a -1.71% change from the preceding trading day.
Positive
Zacks Investment Research
1 week ago
Siga Technologies Inc. (SIGA) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $6.47, indicating a +1.25% shift from the previous trading day.
Neutral
Zacks Investment Research
2 weeks ago
Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts
Siga Technologies Inc. (SIGA) closed the most recent trading day at $6.23, moving -0.24% from the previous trading session.
Negative
Zacks Investment Research
2 weeks ago
Siga Technologies Inc. (SIGA) Advances But Underperforms Market: Key Facts
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.35, representing a +0.32% change from its previous close.
Neutral
GlobeNewsWire
1 month ago
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as TPOXX in the United States, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. TEPOXX is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency (PMDA), in collaboration with the Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses.
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
1 month ago
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?
Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
1 month ago
Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA's tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. Based on this and additional analyses, the study Data Safety and Monitoring Board (DSMB) recommended to stop enrolling patients in the randomized arms of the study. NIAID accepted this recommendation and subsequently decided to take a similar action in the open label arm of this study, which included severe and at-risk of developing severe disease patients. Data analysis is not yet complete for primary endpoint subgroups and detailed secondary and exploratory endpoints.
Positive
Zacks Investment Research
1 month ago
Should Value Investors Buy Siga Technologies (SIGA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
1 month ago
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Siga Technologies (SIGA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Charts implemented using Lightweight Charts™